Tuesday, 23 October 2018

Roche takes on Loxo, Bayer in gene-defined cancer class

/ by  / in / with No comments /

Roche's entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.


from Reuters: Science News https://ift.tt/2OyA8xk
//

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)